Marvell Technology Group Ltd (MRVL)vsPfizer Inc (PFE)
MRVL
Marvell Technology Group Ltd
$316.43
-0.36%
TECHNOLOGY · Cap: $264.11B
PFE
Pfizer Inc
$26.04
+0.15%
HEALTHCARE · Cap: $145.62B
Smart Verdict
WallStSmart Research — data-driven comparison
Pfizer Inc generates 626% more annual revenue ($63.32B vs $8.72B). MRVL leads profitability with a 29.0% profit margin vs 11.8%. MRVL appears more attractively valued with a PEG of 1.64. PFE earns a higher WallStSmart Score of 55/100 (C).
MRVL
Buy55
out of 100
Grade: C
PFE
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MRVL.
Margin of Safety
+13.8%
Fair Value
$30.21
Current Price
$26.04
$4.17 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Keeps 29 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Revenue surging 27.6% year-over-year
Strong operational efficiency at 31.6%
Large-cap with strong market position
Reasonable price relative to book value
Generating 2.2B in free cash flow
Areas to Watch
Expensive relative to growth rate
Trading at 18.7x book value
Grey zone — moderate risk
Premium valuation, high expectations priced in
Distress zone — elevated risk
Expensive relative to growth rate
Earnings declined 10.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRVL
The strongest argument for MRVL centers on Market Cap, Profit Margin, Debt/Equity. Profitability is solid with margins at 29.0% and operating margin at 14.5%. Revenue growth of 27.6% demonstrates continued momentum.
Bull Case : PFE
The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.
Bear Case : MRVL
The primary concerns for MRVL are PEG Ratio, Price/Book, Altman Z-Score. A P/E of 104.0x leaves little room for execution misses.
Bear Case : PFE
The primary concerns for PFE are Altman Z-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
MRVL profiles as a growth stock while PFE is a value play — different risk/reward profiles.
MRVL carries more volatility with a beta of 2.25 — expect wider price swings.
MRVL is growing revenue faster at 27.6% — sustainability is the question.
PFE generates stronger free cash flow (2.2B), providing more financial flexibility.
Bottom Line
MRVL scores higher overall (55/100 vs 55/100), backed by strong 29.0% margins and 27.6% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Marvell Technology Group Ltd
TECHNOLOGY · SEMICONDUCTORS · USA
Marvell Technology, Inc. designs, develops, and sells analog, mixed-signal, digital signal processing, and integrated and independent integrated circuits. The company is headquartered in Wilmington, Delaware.
Visit Website →Pfizer Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.
Visit Website →Compare with Other SEMICONDUCTORS Stocks
Want to dig deeper into these stocks?